Design, Generation, and Evaluation of TCR-, TCR mimetic-, and CAR-based Therapeutics for Cancer Immunotherapy

Festival of Biologics Basel
October 9, 2023

TCRs, antibody TCR-mimetics, and CARs can offer significant advantages over traditional mAb approaches for the treatment of cancer. However, as highly engineered entities, they present new challenges in design, cloning, expression, purification, and analytics. Our workflow platform, used by top biopharma companies, enables the automation, engineering, production, and testing of large panels of these therapeutic molecule candidates. We demonstrate the platform’s high-throughput capability when handling novel molecule-specific designs and its built-in tools for developability and manufacturability assessments.